Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Jul 27;24(15):12063.
doi: 10.3390/ijms241512063.

Equol and Resveratrol Improve Bone Turnover Biomarkers in Postmenopausal Women: A Clinical Trial

Graziamaria Corbi  1 , Vincenzo Nobile  2 , Valeria Conti  3 , Alessandro Cannavo  1 , Vincenzo Sorrenti  4 , Alessandro Medoro  5 , Giovanni Scapagnini  5 , Sergio Davinelli  5
Affiliations
Randomized Controlled Trial

Equol and Resveratrol Improve Bone Turnover Biomarkers in Postmenopausal Women: A Clinical Trial

Graziamaria Corbi et al. Int J Mol Sci. .

Abstract

Estrogen deficiency is a major cause of loss of postmenopausal bone mineral density (BMD). This study aimed to evaluate the effects of equol and resveratrol on bone turnover biomarkers in postmenopausal women. Sixty healthy postmenopausal women were randomly assigned to receive 200 mg fermented soy containing 10 mg equol and 25 mg resveratrol or a placebo for 12 months. Whole-body BMD and bone turnover biomarkers, such as deoxypyridinoline (DPD), tartrate-resistant acid phosphatase 5b (TRACP-5b), osteocalcin, and bone-specific alkaline phosphatase (BAP), were measured at baseline and after 12 months of treatment. At the end of treatment, DPD, osteocalcin, and BAP significantly improved in the active group (p < 0.0001 for all) compared to the placebo group. Conversely, TRACP-5b levels were unaffected by supplementation (p = 0.051). Statistically significant changes in the concentrations of DPD (p < 0.0001), osteocalcin (p = 0.0001), and BAP (p < 0.0001) compared to baseline were also identified. Overall, the intervention significantly increased BMD measured in the whole body (p = 0.0220) compared with the placebo. These data indicate that the combination of equol and resveratrol may positively modulate bone turnover biomarkers and BMD, representing a potential approach to prevent age-related bone loss in postmenopausal women.

Keywords: bone metabolism markers; bone mineral density; equol; menopause; resveratrol.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flowchart of enrolment, intervention allocation, and data analysis.
Figure 2
Figure 2
Concentrations of bone markers and BMD levels in the groups at baseline and after 12 months. The figure shows the concentration of (A) DPD, (B) TRACP-5b, (C) OC, (D) BAP levels, and (E) BMD measured in the whole body at baseline and after 12 months for both groups. The dots represent the outliner values.
Figure 3
Figure 3
Percentage changes in all osteoblastic/osteoclastic parameters and BMD between the placebo and active groups were evaluated. The percentage changes in all bone metabolism markers and BMD were significantly different between the placebo and active groups. The dots represent the outliner values.
Figure 4
Figure 4
Linear regression analysis by group. In the placebo group, no predictors of changes in BMD were identified. Conversely, in the intervention group, a statistically significant association was found between the percentage changes in BAP and the percentage changes in BMD.
See this image and copyright information in PMC

References

    1. Singer A., Exuzides A., Spangler L., O’Malley C., Colby C., Johnston K., Agodoa I., Baker J., Kagan R. Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States. Mayo Clin. Proc. 2015;90:53–62. doi: 10.1016/j.mayocp.2014.09.011. - DOI - PubMed
    1. Clynes M.A., Harvey N.C., Curtis E.M., Fuggle N.R., Dennison E.M., Cooper C. The epidemiology of osteoporosis. Br. Med. Bull. 2020;133:105–117. doi: 10.1093/bmb/ldaa005. - DOI - PMC - PubMed
    1. Cheng C.H., Chen L.R., Chen K.H. Osteoporosis Due to Hormone Imbalance: An Overview of the Effects of Estrogen Deficiency and Glucocorticoid Overuse on Bone Turnover. Int. J. Mol. Sci. 2022;23:1376. doi: 10.3390/ijms23031376. - DOI - PMC - PubMed
    1. Kuo T.R., Chen C.H. Bone biomarker for the clinical assessment of osteoporosis: Recent developments and future perspectives. Biomark. Res. 2017;5:18. doi: 10.1186/s40364-017-0097-4. - DOI - PMC - PubMed
    1. Nishizawa Y., Miura M., Ichimura S., Inaba M., Imanishi Y., Shiraki M., Takada J., Chaki O., Hagino H., Fukunaga M., et al. From the Japan Osteoporosis Society Bone Turnover Marker Investigation Committee. Executive summary of the Japan Osteoporosis Society Guide for the Use of Bone Turnover Markers in the Diagnosis and Treatment of Osteoporosis (2018 Edition) Clin. Chim. Acta. 2019;498:101–107. doi: 10.1016/j.cca.2019.08.012. - DOI - PubMed

Publication types

LinkOut - more resources